Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | ubiquitin specific peptidase 1 | Starlite/ChEMBL | No references |
Homo sapiens | isocitrate dehydrogenase 1 (NADP+), soluble | Starlite/ChEMBL | No references |
Homo sapiens | SMAD family member 2 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | MH2 domain containing protein | SMAD family member 2 | 467 aa | 405 aa | 31.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | Smad1 | 0.001 | 0.0037 | 0.0037 |
Brugia malayi | MH2 domain containing protein | 0.0144 | 0.1179 | 0.1179 |
Loa Loa (eye worm) | Smad1 | 0.001 | 0.0037 | 0.0037 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0144 | 0.1179 | 0.1179 |
Echinococcus multilocularis | NADP dependent isocitrate dehydrogenase | 0.0019 | 0.0116 | 0.065 |
Brugia malayi | hypothetical protein | 0.0498 | 0.4186 | 0.4186 |
Plasmodium vivax | isocitrate dehydrogenase [NADP], mitochondrial, putative | 0.0019 | 0.0116 | 0.5 |
Echinococcus multilocularis | isocitrate dehydrogenase 2 (NADP+) | 0.0019 | 0.0116 | 0.065 |
Brugia malayi | MH2 domain containing protein | 0.001 | 0.0037 | 0.0037 |
Echinococcus multilocularis | isocitrate dehydrogenase | 0.0019 | 0.0116 | 0.065 |
Echinococcus granulosus | Cyclin dependent kinase 2 associated protein | 0.0152 | 0.1247 | 1 |
Trypanosoma cruzi | isocitrate dehydrogenase [NADP], mitochondrial precursor, putative | 0.0019 | 0.0116 | 0.5 |
Leishmania major | isocitrate dehydrogenase [NADP], mitochondrial precursor, putative | 0.0019 | 0.0116 | 0.5 |
Schistosoma mansoni | TGF-beta signal transducer Smad2 | 0.001 | 0.0037 | 0.0025 |
Echinococcus multilocularis | NADP dependent isocitrate dehydrogenase | 0.0019 | 0.0116 | 0.065 |
Brugia malayi | isocitrate dehydrogenase | 0.0019 | 0.0116 | 0.0116 |
Schistosoma mansoni | NADP-specific isocitrate dehydrogenase | 0.0019 | 0.0116 | 0.0104 |
Echinococcus granulosus | NADP dependent isocitrate dehydrogenase | 0.0019 | 0.0116 | 0.065 |
Trypanosoma brucei | isocitrate dehydrogenase [NADP], mitochondrial precursor, putative | 0.0019 | 0.0116 | 0.5 |
Brugia malayi | Isocitrate dehydrogenase | 0.0019 | 0.0116 | 0.0116 |
Schistosoma mansoni | smad1 5 8 and | 0.001 | 0.0037 | 0.0025 |
Schistosoma mansoni | smad | 0.001 | 0.0037 | 0.0025 |
Toxoplasma gondii | isocitrate dehydrogenase | 0.0019 | 0.0116 | 0.5 |
Onchocerca volvulus | Diphthamide biosynthesis protein 7 homolog | 0.0152 | 0.1247 | 0.5 |
Mycobacterium tuberculosis | Probable isocitrate dehydrogenase [NADP] Icd1 (oxalosuccinate decarboxylase) (IDH) (NADP+-specific ICDH) (IDP) | 0.0019 | 0.0116 | 0.5 |
Brugia malayi | MH1 domain containing protein | 0.001 | 0.0037 | 0.0037 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.001 | 0.0037 | 0.0037 |
Trypanosoma cruzi | isocitrate dehydrogenase, putative | 0.0019 | 0.0116 | 0.5 |
Schistosoma mansoni | smad1 5 8 and | 0.001 | 0.0037 | 0.0025 |
Loa Loa (eye worm) | isocitrate dehydrogenase | 0.0019 | 0.0116 | 0.0116 |
Schistosoma mansoni | smad1 5 8 and | 0.001 | 0.0037 | 0.0025 |
Schistosoma mansoni | serine/threonine protein kinase | 0.1182 | 1 | 1 |
Echinococcus multilocularis | Cyclin dependent kinase 2 associated protein | 0.0152 | 0.1247 | 1 |
Schistosoma mansoni | Smad4 | 0.001 | 0.0037 | 0.0025 |
Trypanosoma brucei | isocitrate dehydrogenase, putative | 0.0019 | 0.0116 | 0.5 |
Loa Loa (eye worm) | CAMK/CAMKL/CHK1 protein kinase | 0.1182 | 1 | 1 |
Loa Loa (eye worm) | MH1 domain-containing protein | 0.001 | 0.0037 | 0.0037 |
Toxoplasma gondii | isocitrate dehydrogenase | 0.0019 | 0.0116 | 0.5 |
Brugia malayi | MH2 domain containing protein | 0.001 | 0.0037 | 0.0037 |
Loa Loa (eye worm) | hypothetical protein | 0.0152 | 0.1247 | 0.1247 |
Brugia malayi | MH1 domain containing protein | 0.001 | 0.0037 | 0.0037 |
Plasmodium falciparum | isocitrate dehydrogenase [NADP], mitochondrial | 0.0019 | 0.0116 | 0.5 |
Schistosoma mansoni | deleted in oral cancer 1/cdk2-associated protein-like | 0.0152 | 0.1247 | 0.1237 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0144 | 0.1179 | 0.1179 |
Echinococcus multilocularis | NADP dependent isocitrate dehydrogenase | 0.0019 | 0.0116 | 0.065 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 4.4668 uM | PubChem BioAssay. Inhibitors of USP1/UAF1: Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 8.9125 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] | ChEMBL. | No reference |
Potency (functional) | 15.8489 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | 18.3564 uM | PubChem BioAssay. qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PubChem BioAssay. qHTS for Activators of Integrin-Mediated Alleviation for Muscular Dystrophy. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 39.8107 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.